| Autor: |
Li, Zheqi, McGinn, Olivia, Wu, Yang, Bahreini, Amir, Priedigkeit, Nolan M., Ding, Kai, Onkar, Sayali, Lampenfeld, Caleb, Sartorius, Carol A., Miller, Lori, Rosenzweig, Margaret, Cohen, Ofir, Wagle, Nikhil, Richer, Jennifer K., Muller, William J., Buluwela, Laki, Ali, Simak, Bruno, Tullia C., Vignali, Dario A. A., Fang, Yusi |
| Předmět: |
|
| Zdroj: |
Nature Communications; 4/19/2022, Vol. 13 Issue 1, p1-18, 18p |
| Abstrakt: |
Estrogen receptor alpha (ER/ESR1) is frequently mutated in endocrine resistant ER-positive (ER+) breast cancer and linked to ligand-independent growth and metastasis. Despite the distinct clinical features of ESR1 mutations, their role in intrinsic subtype switching remains largely unknown. Here we find that ESR1 mutant cells and clinical samples show a significant enrichment of basal subtype markers, and six basal cytokeratins (BCKs) are the most enriched genes. Induction of BCKs is independent of ER binding and instead associated with chromatin reprogramming centered around a progesterone receptor-orchestrated insulated neighborhood. BCK-high ER+ primary breast tumors exhibit a number of enriched immune pathways, shared with ESR1 mutant tumors. S100A8 and S100A9 are among the most induced immune mediators and involve in tumor-stroma paracrine crosstalk inferred by single-cell RNA-seq from metastatic tumors. Collectively, these observations demonstrate that ESR1 mutant tumors gain basal features associated with increased immune activation, encouraging additional studies of immune therapeutic vulnerabilities. Mutations of ESR1, the gene encoding the estrogen receptor alpha, are associated with acquired resistance to therapy in luminalbreast cancer. Here the authors show that ESR1 mutant tumors gain basal-like features with increased expression of basal cytokeratines and immune activation. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink